Overview

Amphotericin B Suspension in Refractory Chronic Sinusitis

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and efficacy of Amphotericin B suspension versus placebo in the complete resolution of key chronic sinusitis symptoms during 16 weeks of treatment in patients with refractory, postsurgical CS.
Phase:
Phase 3
Details
Lead Sponsor:
Accentia Biopharmaceuticals
Treatments:
Amphotericin B
Liposomal amphotericin B